Karyopharm Therapeutics (FRA:25K) Short Percentage of Float

View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Karyopharm Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Karyopharm Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karyopharm Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Short Percentage of Float falls into.

Karyopharm Therapeutics (FRA:25K) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

KPTI:USA

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics (FRA:25K) Headlines

No Headlines